Thor Medical A (TRMED.OL) Stock Price
Thor Medical A Price
Revenue has compounded at 8.6% per year over the past 13 years to 439,000.00 NOK. Thor Medical A's net margin stands at -13,214.8%, up from -14,470.5% several years earlier. Analysts set a median price target of 5.10 NOK, implying 14.5% above the current price. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus.
Thor Medical A stock price
Thor Medical A business model & stock analysis
Frequently asked questions about Thor Medical A
The business model of Nordic Nanovector ASA focuses on the development and commercialization of targeted therapies for hematological cancers. The company specializes in the development of innovative antibody-radionuclide conjugates (ARCs), which deliver highly specific radiation directly to cancer cells. By targeting and effectively treating cancers such as non-Hodgkin’s lymphoma, Nordic Nanovector aims to improve patient outcomes and quality of life. The company’s dedication to research, development, and commercialization of novel therapies places it at the forefront of the fight against hematological cancers, making Nordic Nanovector a prominent player in the biotechnology industry.
Nordic Nanovector ASA is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Nordic Nanovector ASA in the market are other companies operating in the field of targeted therapies for cancer treatment. However, Nordic Nanovector ASA maintains a unique position due to its innovative technology and product pipeline. With its lead candidate, Betalutin®, Nordic Nanovector ASA aims to provide a superior treatment option for patients suffering from non-Hodgkin's lymphoma. Despite facing competition, Nordic Nanovector ASA's strategic focus and ongoing advancements position it as a prominent player in the market.
Nordic Nanovector ASA is a biopharmaceutical company based in Norway. Founded in 2009, the company focuses on the development and commercialization of innovative targeted therapeutics for the treatment of hematological malignancies. Nordic Nanovector's flagship product candidate is Betalutin®, a novel radioimmunotherapy designed to improve patient outcomes in non-Hodgkin lymphoma. With a strong background in radioimmunotherapy and precision medicine, Nordic Nanovector aims to revolutionize cancer treatment by delivering more effective and less toxic therapies. Through strategic collaborations and continuous research and development efforts, the company strives to advance the field of precision oncology and bring hope to patients worldwide. Nordic Nanovector ASA continues to pursue its mission of improving cancer care and addressing unmet medical needs.
Nordic Nanovector ASA, a leading biotechnology company, has achieved several significant milestones. The company successfully completed the phase 1 clinical trial for its innovative targeted therapy, Betalutin, designed for the treatment of non-Hodgkin lymphoma (NHL). Furthermore, Nordic Nanovector ASA received Fast Track designation from the U.S. FDA for Betalutin, recognizing its potential to address unmet medical needs. The company also secured Orphan Drug Designation for Betalutin from both the FDA and the European Medicines Agency (EMA), providing further regulatory support. These achievements highlight Nordic Nanovector ASA's commitment to developing groundbreaking therapies and solidify its position as a key player in the field of oncology.
Nordic Nanovector ASA primarily operates in Norway, as it is a Norwegian biopharmaceutical company. However, the company's presence is not limited to Norway alone. Nordic Nanovector ASA has expanded its reach to other countries and regions as well, including the United States, throughout Europe, and Asia. With its focus on developing innovative targeted therapies for hematological cancers, Nordic Nanovector ASA is continuously seeking to collaborate with global partners and extend its presence in key markets worldwide.
Nordic Nanovector ASA represents a set of core values and a corporate philosophy that guides its operations. The company believes in innovation, scientific excellence, and a patient-centered approach. Nordic Nanovector is dedicated to developing targeted therapies for patients with hematological malignancies, aiming to improve their quality of life and overall survival. By leveraging its proprietary technology platform, the company aims to make a meaningful impact in the field of precision medicine. Nordic Nanovector ASA strives to collaborate with partners and stakeholders to accelerate the development of novel treatments and bring hope to patients in need.
Analysts currently set an average price target of 5.10 NOK for the Thor Medical A stock (median: 5.10 NOK), implying +14.5 % versus the latest price. The consensus is based on 9 analyst ratings.
9 analysts currently rate the Thor Medical A stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Thor Medical A to generate revenue of 20.00 M NOK and earnings per share of -0.27 NOK.
Converted at the current exchange rate, the Thor Medical A share trades at 0.42 EUR (4.45 NOK).
The Thor Medical A share (TRMED.OL) is listed on 5 stock exchanges, including: London (0R6Y.L), SIX (Zürich) (8NN.SW), Frankfurt (8NN.F), München (8NN.MU), Düsseldorf (8NN.DU).
Nordic Nanovector ASA is a Norwegian company specializing in the development of innovative therapies for the treatment of non-Hodgkin lymphomas. The company operates with a unique business model based on scientific research and strategic partnerships. The company focuses on the development of innovative antibody therapies that target specific antigens of non-Hodgkin lymphomas. They also developed Betalutin®, a radioisotope-based conjugate that aims to selectively destroy cancer cells. Nordic Nanovector ASA works closely with strategic partners to advance the development and commercialization of its products, aiming to reduce costs and risks while increasing the reach and success of its products. In summary, Nordic Nanovector ASA develops innovative antibody therapies and radioisotope-based conjugates to fight non-Hodgkin lymphomas, working with strategic partners to drive product development and commercialization, and pursuing a research strategy focused on scientific excellence and long-term success.
The expected revenue of Thor Medical A is 20.00 M NOK. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Thor Medical A is -63.73 M NOK. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Thor Medical A is currently -16.59. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Thor Medical A stock.
The price-to-sales ratio (P/S) of Thor Medical A is currently 52.88. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Thor Medical A stock.
The Eulerpool Quality Score for Thor Medical A is 3/10.
The ISIN of Thor Medical A is NO0010597883. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Thor Medical A is A1H64K. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Thor Medical A is TRMED.OL. The ticker symbol is used to trade Thor Medical A shares on the stock exchange.
Thor Medical A stock
Thor Medical A Peer Group
Thor Medical A Ticker
Thor Medical A FIGI
All fundamentals and in-depth analysis of Thor Medical A
Our stock analysis for Thor Medical A stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Thor Medical A. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.